首页> 外文OA文献 >Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease
【2h】

Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease

机译:探索监测抗TNFα药物和抗体水平在炎症性肠病治疗中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Crohn’s disease and ulcerative colitis are chronic inflammatory gastrointestinal disorders which often result in significant morbidity or surgery. Current treatment options are not curative and may cause significant adverse effects. The introduction of anti-tumour necrosis factor alpha (anti-TNFα) therapy over a decade ago was a welcome addition to the therapeutic armamentarium and revolutionized the treatment of inflammatory bowel disease (IBD). Despite their relative success, a significant proportion of patients with IBD fail to respond or subsequently lose response anti-TNFα therapy. This review identifies and explores the role of drug levels and immunogenicity (antibody formation) on the efficacy of anti-TNFα therapy and details how monitoring these parameters may help to optimize the management of patients with IBD.
机译:克罗恩氏病和溃疡性结肠炎是慢性炎症性胃肠道疾病,通常会导致严重的发病或手术。当前的治疗方法无法治愈,可能会导致严重的不良反应。十多年前,抗肿瘤坏死因子α(anti-TNFα)治疗的引入是治疗性备件库中令人欢迎的补充,并彻底改变了炎症性肠病(IBD)的治疗方法。尽管取得了相对的成功,但仍有很大一部分IBD患者对抗TNFα治疗无效或失去反应。这篇综述鉴定并探讨了药物水平和免疫原性(抗体形成)对抗TNFα疗法功效的作用,并详细介绍了如何监测这些参数可以帮助优化IBD患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号